Proteus Digital Health, Inc

Belkins
Welcome to Proteus Digital Health, a leading innovator spearheading the Digital Medicines revolution. Join our unique collection of innovative engineers, scientists, designers, developers, clinicians, and other digital health pioneers, and assist us with achieving our compelling vision, “Healthcare for Everyone, Everywhere.” Proteus is creating a new category of pharmaceuticals: Digital Medicines. Digital Medicine includes drugs that communicate when they’ve been taken, wearable sensors that capture physiologic response, applications that support patient self-care and physician decision making, and data analytics to serve the needs of doctors and health systems. The goal of Digital Medicine is to empower patients and their families, enable physicians and health systems to more effectively manage risk and ensure that outcomes are reliably achieved.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

NOVARTIS DEMANDS OUTSIDE COUNSEL MAKE TOUGH DIVERSITY GUARANTEES

Bloomberg Law | February 13, 2020

news image

Novartis AG is demanding that its 22 “preferred” Big Law firms make specific diverse staffing commitments for each engagement with the pharma giant or face punishment in the form of reduced payments. Through the new program announced on Wednesday, Novartis is also requiring its outside counsel to commit that at least 30% of billable associate time and 20% of partner time will be provided by women, racially or ethnically diverse professionals, or members of the LGBT community. If firm...

Read More

ANTI-PARASITIC DRUG HALTS CORONAVIRUS REPLICATION IN LAB-GROWN CELLS WITHIN 48 HOURS

GEN | April 06, 2020

news image

An anti-parasitic drug that is available around the world stops SARS-CoV-2 coronavirus from replicating in cells within a couple of days, according to findings from in vitro studies by Monash University’s Biomedicine Discovery Institute (BDI), working with the Peter Doherty Institute of Infection and Immunity. BDI research lead Kylie Wagstaff, PhD, said the studies showed that the drug, ivermectin, started to become effective against SARS-CoV-2 in lab-grown cells within just a day. “...

Read More

PRACTICE MANAGEMENT

ROYALTY PHARMA ACQUIRES ROYALTY INTEREST IN ORLADEYO AND BCX9930 FROM BIOCRYST PHARMACEUTICALS

Royalty Pharma | December 08, 2020

news image

Royalty Pharma, BioCryst Pharmaceuticals, Inc. what's more, Athyrium Capital Management, LP today declared exchanges adding up to $325 million in financing for BioCryst, with $250 million accessible at shutting, to help the dispatch of ORLADEYO™ (berotralstat) in genetic angioedema (HAE) and the advancement of its oral Factor D inhibitor, BCX9930. Royalty Pharma will furnish BioCryst with a forthright money installment of $125 million and will get eminences of 8.75% on d...

Read More

IONIS AND GENUITY SCIENCE ANNOUNCE AGREEMENT DESIGNED TO RAPIDLY TRANSLATE GENOMIC INSIGHTS INTO THERAPEUTICS

Prnewswire | October 01, 2020

news image

Genuity Science, a genomics and data insights organization and Ionis Pharmaceuticals (NASDAQ: IONS), the leader in antisense therapeutics, today announced a broad, multi-year collaboration aimed at accelerating the discovery and development of innovative therapeutics across a range of up to 20 diseases. The collaboration is expected to play an important role in allowing Ionis to continue delivering transformational medicines to patients for many years to come. Genuity Science's approach comb...

Read More

Bloomberg Law | February 13, 2020

news image

NOVARTIS DEMANDS OUTSIDE COUNSEL MAKE TOUGH DIVERSITY GUARANTEES

Novartis AG is demanding that its 22 “preferred” Big Law firms make specific diverse staffing commitments for each engagement with the pharma giant or face punishment in the form of reduced payments. Through the new program announced on Wednesday, Novartis is also requiring its outside counsel to commit that at least 30% of billable associate time and 20% of partner time will be provided by women, racially or ethnically diverse professionals, or members of the LGBT community. If firm...

Read More

GEN | April 06, 2020

news image

ANTI-PARASITIC DRUG HALTS CORONAVIRUS REPLICATION IN LAB-GROWN CELLS WITHIN 48 HOURS

An anti-parasitic drug that is available around the world stops SARS-CoV-2 coronavirus from replicating in cells within a couple of days, according to findings from in vitro studies by Monash University’s Biomedicine Discovery Institute (BDI), working with the Peter Doherty Institute of Infection and Immunity. BDI research lead Kylie Wagstaff, PhD, said the studies showed that the drug, ivermectin, started to become effective against SARS-CoV-2 in lab-grown cells within just a day. “...

Read More

PRACTICE MANAGEMENT

Royalty Pharma | December 08, 2020

news image

ROYALTY PHARMA ACQUIRES ROYALTY INTEREST IN ORLADEYO AND BCX9930 FROM BIOCRYST PHARMACEUTICALS

Royalty Pharma, BioCryst Pharmaceuticals, Inc. what's more, Athyrium Capital Management, LP today declared exchanges adding up to $325 million in financing for BioCryst, with $250 million accessible at shutting, to help the dispatch of ORLADEYO™ (berotralstat) in genetic angioedema (HAE) and the advancement of its oral Factor D inhibitor, BCX9930. Royalty Pharma will furnish BioCryst with a forthright money installment of $125 million and will get eminences of 8.75% on d...

Read More

Prnewswire | October 01, 2020

news image

IONIS AND GENUITY SCIENCE ANNOUNCE AGREEMENT DESIGNED TO RAPIDLY TRANSLATE GENOMIC INSIGHTS INTO THERAPEUTICS

Genuity Science, a genomics and data insights organization and Ionis Pharmaceuticals (NASDAQ: IONS), the leader in antisense therapeutics, today announced a broad, multi-year collaboration aimed at accelerating the discovery and development of innovative therapeutics across a range of up to 20 diseases. The collaboration is expected to play an important role in allowing Ionis to continue delivering transformational medicines to patients for many years to come. Genuity Science's approach comb...

Read More